TransEnterix, Inc. (NYSE:TRXC) stock is currently pricing at roughly $0.65. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 2 analysts covering the company at $3.25. That suggests shares of the stock may have another 80 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $3.75, which would imply another -377 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 2 “Buy” ratings in place. At the same time, 2 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 2 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.

Analysts at Raymond James took a look at TRXC shares in a research note released on Jan 19, 2017, and issued a Mkt Perform rating to this company. Lake Street analysts provided their own take on company recently as well. In a research note published on May 11, 2016,the house assigned a Hold rating to this stock. According to a piece that hit the wires on May 27, 2014, researchers at RBC Capital Mkts reconsidered their prior rating on the stock, and upped it from Perform to Outperform.

TransEnterix, Inc. (TRXC) Cap Table Analysis

Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 16.72 percent of the stock.

If we take a more granular look, Dr. Jane H. Hsiao, PhD is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 15,812,681 shares, representing a total current market value of roughly $10278242.65. Jeffrey G. Spragens is another major player among company insiders, currently holding 2,545,285 shares as of 2.06%, carrying a current market value of $1654435.25. Dr. Charles J. Filipi,M.D. is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 707,046 shares, valued at around $459579.9 as of recent close.

We noted a few insider transactions for the stock recently as well.

In a transaction on 2017-01-04, the company’s 10% Owner SOFAR, S.p.A Purchased 3,722,685 company shares for 5211760. That means, once accounting for this transaction, the 10% Owner is left with a stake of 19,266,098 shares, carrying a current total market value of $12522964. In addition, by means of a transaction dated 2016-08-22, Director Biffi Andrea purchased 40,000 shares worth $56000. After that transaction, this investor is left with a total holding of 90,000 shares, representing a total investment value of $58500. We also noted a 2016-06-14 transaction in which TRXC Chief Technology Officer Fernando Anthony C. J. purchased 27,000 shares at a stock price of $1.46, carrying a total value of $39420, after which, this insider’s investment stands at 27,000 shares, with an overall financial value of $17550.

TransEnterix, Inc. (NYSE:TRXC) Earnings View 

In the company’s last quarter, TRXC EPS moved to $-0.12 from $-0.11 compared sequentially with the prior quarter. Revenues for the company came in at $0.05MM. This stacks up against $1.47MM, on a sequential basis.

How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $-0.11 per share on $1.33MM in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $-0.12 to $-0.10. On a year-over-year basis, that compares with an EPS comp of $-0.12.